(Q47583383)

English

MxA Gene Expression Analysis as an Interferon-β Bioactivity Measurement in Patients with Multiple Sclerosis and the Identification of Antibody-Mediated Decreased Bioactivity

scientific article published on January 1, 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/14529316

MxA Gene Expression Analysis as an Interferon-β Bioactivity Measurement in Patients with Multiple Sclerosis and the Identification of Antibody-Mediated Decreased Bioactivity (English)

reason for preferred rank

most precise value

1 reference

10.1007/BF03260016

https://api.crossref.org/works/10.1007/BF03260016

18 March 2024

MxA gene expression analysis as an interferon-beta bioactivity measurement in patients with multiple sclerosis and the identification of antibody-mediated decreased bioactivity (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14529316

18 March 2024

multiple sclerosis

0 references

1 reference

based on heuristic

inferred from title

author name string

Andrew Pachner

1

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/14529316

Kavitha Narayan

2

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/14529316

Nicholson Price

3

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/14529316

Marie Hurd

4

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/14529316

Donna Dail

5

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/14529316

language of work or name

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14529316

18 March 2024

publication date

1 January 2003

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/14529316

full work available at URL

http://link.springer.com/content/pdf/10.1007/BF03260016.pdf

Portable Document Format

1 reference

10.1007/BF03260016

https://api.crossref.org/works/10.1007/BF03260016

18 March 2024

http://link.springer.com/article/10.1007/BF03260016/fulltext.html

1 reference

10.1007/BF03260016

https://api.crossref.org/works/10.1007/BF03260016

18 March 2024

http://link.springer.com/content/pdf/10.1007/BF03260016

1 reference

10.1007/BF03260016

https://api.crossref.org/works/10.1007/BF03260016

18 March 2024

Molecular Diagnosis and Therapy

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/14529316

7

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/14529316

17-25

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/14529316

1

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/14529316

https://scigraph.springernature.com/pub.10.1007/bf03260016

0 references

Mapping of IFN-beta epitopes important for receptor binding and biologic activation: comparison of results achieved using antibody-based methods and alanine substitution mutagenesis

1 reference

https://api.crossref.org/works/10.1007%2FBF03260016

21 January 2018

Self-assembly of human MxA GTPase into highly ordered dynamin-like oligomers

1 reference

https://api.crossref.org/works/10.1007%2FBF03260016

21 January 2018

The human intracellular Mx-homologous protein is specifically induced by type I interferons.

1 reference

https://api.crossref.org/works/10.1007%2FBF03260016

21 January 2018

Evaluation of bioavailability of three types of IFNbeta in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantification.

1 reference

https://api.crossref.org/works/10.1007%2FBF03260016

21 January 2018

Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients.

1 reference

https://api.crossref.org/works/10.1007%2FBF03260016

21 January 2018

Neutralising antibodies to interferon beta during the treatment of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1007%2FBF03260016

21 January 2018

Bioequivalence and the immunogenicity of biopharmaceuticals

1 reference

https://api.crossref.org/works/10.1007%2FBF03260016

21 January 2018

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

1 reference

https://api.crossref.org/works/10.1007%2FBF03260016

21 January 2018

The expression of potency of neutralizing antibodies for interferons and other cytokines

1 reference

https://api.crossref.org/works/10.1007%2FBF03260016

21 January 2018

Neutralizing antibodies reduce MxA protein induction in interferon-beta-1a-treated MS patients.

1 reference

https://api.crossref.org/works/10.1007%2FBF03260016

21 January 2018

Messenger RNA degradation in eukaryotes

1 reference

https://api.crossref.org/works/10.1007%2FBF03260016

21 January 2018

Improvement of molecular monitoring of residual disease in leukemias by bedside RNA stabilization

1 reference

https://api.crossref.org/works/10.1007%2FBF03260016

21 January 2018

Formation of a uniquely stable type I interferon receptor complex by interferon beta is dependent upon particular interactions between interferon beta and its receptor and independent of tyrosine phosphorylation

1 reference

https://api.crossref.org/works/10.1007%2FBF03260016

21 January 2018

Complex immunomodulatory effects of interferon-beta in multiple sclerosis include the upregulation of T helper 1-associated marker genes.

1 reference

https://api.crossref.org/works/10.1007%2FBF03260016

21 January 2018

Interferon-beta directly influences monocyte infiltration into the central nervous system.

1 reference

https://api.crossref.org/works/10.1007%2FBF03260016

21 January 2018

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/14529316

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Stabilization of mRNA expression in whole blood samples.

1 reference

https://pubmed.ncbi.nlm.nih.gov/14529316

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The neutralization of interferons by antibody. I. Quantitative and theoretical analyses of the neutralization reaction in different bioassay systems

1 reference

https://pubmed.ncbi.nlm.nih.gov/14529316

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Degradation of mRNA in eukaryotes

1 reference

https://pubmed.ncbi.nlm.nih.gov/14529316

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Measurement of antibodies to interferon beta in patients with multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/14529316

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of multiple sclerosis patients with interferon-beta primes monocyte-derived macrophages for apoptotic cell death

1 reference

https://pubmed.ncbi.nlm.nih.gov/14529316

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

On the evaluation of disability in multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/14529316

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anticytokine antibodies in beta interferon-treated MS patients and the need for testing: plight of the practicing neurologist

1 reference

https://pubmed.ncbi.nlm.nih.gov/14529316

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

MRI and clinical activity in MS patients after terminating treatment with interferon beta-1b

1 reference

https://pubmed.ncbi.nlm.nih.gov/14529316

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ELISA methods for the analysis of antibody responses induced in multiple sclerosis patients treated with recombinant interferon-beta

1 reference

https://pubmed.ncbi.nlm.nih.gov/14529316

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oligodendrocytes express an alpha/beta-interferon-susceptible Mx gene: molecular characterization of the encoded protein

1 reference

https://pubmed.ncbi.nlm.nih.gov/14529316

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The significance of neutralizing antibodies in patients with multiple sclerosis treated with interferon beta

1 reference

https://pubmed.ncbi.nlm.nih.gov/14529316

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/14529316

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Commentary on neutralizing antibodies to interferon beta in patients with multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/14529316

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies

1 reference

https://pubmed.ncbi.nlm.nih.gov/14529316

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://pubmed.ncbi.nlm.nih.gov/14529316

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparative study of the relative bioavailability of different interferon beta preparations

1 reference

https://pubmed.ncbi.nlm.nih.gov/14529316

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mx proteins in blood leukocytes for monitoring interferon beta-1b therapy in patients with MS

1 reference

https://pubmed.ncbi.nlm.nih.gov/14529316

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The neutralization of interferons by antibody. II. Neutralizing antibody unitage and its relationship to bioassay sensitivity: the tenfold reduction unit

1 reference

https://pubmed.ncbi.nlm.nih.gov/14529316

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antibodies to beta-interferons in multiple sclerosis: can we neutralize the controversy?

18

1 reference

10.1007/BF03260016

https://api.crossref.org/works/10.1007/BF03260016

18 March 2024

Annals of Neurology

19

44

505

author name string

N Richert

publication date

1998

1 reference

10.1007/BF03260016

https://api.crossref.org/works/10.1007/BF03260016

18 March 2024

Journal of Leukocyte Biology

36

70

745

author name string

J Weyenbergh Van

publication date

2001

1 reference

10.1007/BF03260016

https://api.crossref.org/works/10.1007/BF03260016

18 March 2024

Identifiers

10.1007/BF03260016

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/14529316

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/14529316

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47583383&oldid=2104794482"